Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Alnylam and Sanofi report RNAi success
by Michael McCoy
September 25, 2017
| A version of this story appeared in
Volume 95, Issue 38
Patisiran, an RNA interference drug being developed by Alnylam and Sanofi, met its primary goals in a Phase III study as a treatment for hereditary ATTR amyloidosis, a rare genetic disease. Alnylam plans to file a New Drug Application later this year. “We are proud to report the first-ever positive Phase III results for an RNAi therapeutic,” says Alnylam CEO John Maraganore. Alnylam’s stock price soared more than 20% on the news. The firm earlier experienced setbacks for two other RNAi drugs, revusiran and fitusiran.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X